Viewing Study NCT07081633


Ignite Creation Date: 2025-12-25 @ 2:44 AM
Ignite Modification Date: 2026-02-24 @ 8:50 AM
Study NCT ID: NCT07081633
Status: RECRUITING
Last Update Posted: 2025-10-29
First Post: 2025-06-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module